Endometrial surface (luminal epithelium)

The endometrial surface, specifically the luminal epithelium, is the specialized single layer of cells that lines the inner cavity of the uterus and serves as the primary site for embryo attachment and implantation [2, 17]. This tissue layer is highly dynamic, undergoing cyclic morphological and molecular transformations in response to ovarian hormones, estrogen and progesterone, to achieve a receptive state during the "window of implantation" [8, 18]. While the surface itself is an anatomical structure rather than a single molecular target, it is the site of expression for critical therapeutic targets such as integrin alpha-v beta-3, L-selectin ligands, and the cyclic nucleotide-gated channel beta 3 (CNGB3) [1, 16, 17]. Pharmacological interventions, including progesterone and human chorionic gonadotropin (hCG), target this environment to improve fertility or manage conditions like endometriosis where ectopic endometrial-like cells adhere to peritoneal surfaces [6, 13, 16, 19]. Dysregulation of the surface epithelium's molecular profile is significantly associated with recurrent implantation failure, miscarriages, and the development of endometrial cancer [11, 12, 18].

Other names

Endometrial luminal epitheliumUterine luminal surfaceEndometrial apical surfaceUterine lining epitheliumSurface endometrial epithelium

Drugs modulate the endometrial surface by binding to nuclear or membrane-bound receptors to alter the expression of adhesion molecules, cytokines, and ion channels, thereby regulating the window of implantation or inhibiting pathological cell growth [6, 9, 14, 16]. Experimental therapies may use surface-specific peptides to target receptors like CNGB3 for the delivery of pro-apoptotic agents in endometriosis [1, 16].